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Objectives. To determine whether atrial fibrillation (AF) alone
affects the fibrinocoagulation system, we examined the relation
between fibrinocoagulation activity and duration of AF in patients
with paroxysmal AF (PAF).
Background. Patients with chronic AF are at higher risk for
stroke and a hypercoagulative state. It is not clear whether this
hypercoagulative state is attributable to AF alone or to the
underlying disease. There are no reports on the fibrinocoagulation
properties in PAF.
Methods. Fibrinocoagulation variables in 21 patients with PAF
were measured during AF and 7 days after recovery of sinus
rhythm. There were positive correlations between the duration of
AF and beta-thromboglobulin, platelet factor 4, thrombin-
antithrombin III complex and fibrinogen. These variables in-
creased significantly 12 h after the occurrence of PAF; thus,
patients were classified into two groups according to the duration
of PAF: PAF-I group (<12 h, n 5 10), PAF-II group (>212 h, n 5
11). Nine age-matched, healthy subjects formed the control group.
Results. Levels of beta-thromboglobulin and platelet factor 4
were significantly higher (p < 0.001) by two-way repeated mea-
sures analysis of variance (ANOVA), and thrombin-antithrombin
III complex and fibrinogen levels tended to be but were not
significantly higher (p 5 0.06, ANOVA), in the PAF-II group than
in the PAF-I group. There were no significant differences between
groups in activated partial thromboplastin time, D-dimer or
plasmin inhibitor complex.
Conclusions. These results indicate that AF itself enhances
platelet aggregation and coagulation, which are influenced by the
duration of AF. The acceleration of platelet activity and coagula-
bility occurred 12 h after the occurrence of AF.
(J Am Coll Cardiol 1997;29:106–12)
q1997 by the American College of Cardiology
It is well known that the coagulative state in patients with
chronic atrial fibrillation (CAF) is higher than that in patients
with normal sinus rhythm (1–6) and that the incidence of
thromboembolism is also significantly higher in these patients
(7–12). Therefore, CAF is an important risk factor of cerebral
embolism. In addition, some investigators have reported that
(13–15) paroxysmal atrial fibrillation (PAF) might also be a
risk factor for stroke. However, to our knowledge there are no
reports of a change in coagulative state in patients with PAF.
In patients with CAF, the hypercoagulative state was com-
pared with that in patients without atrial fibrillation (AF)
(1–6). Thus, it is not clear whether this hypercoagulative state
in AF is attributable to AF alone or to the disease that
underlies AF.
We previously reported (16) that PAF did not affect the
coagulation system within an average of 6 h after onset of PAF.
However, it is possible that a longer duration of PAF acceler-
ates the coagulation system. Therefore, we examined the
changes in coagulative variables in patients with PAF to
determine whether the duration of PAF affects the coagulative
system.
Methods
Subjects. The study group included 21 patients with PAF
(15 men, 6 women; mean [6SD] age 59.16 9.5 years, range 43
to 77). Patients with valvular disease, ischemic heart disease,
hyperlipidemia, diabetes mellitus, dilated cardiomyopathy and
sick sinus syndrome, or those with a past history of cerebral
infarction or heart failure, were eliminated from the study.
Two patients with high levels of platelet activity, as determined
previously, were also excluded from the study because silent
cerebral infarction was found during a follow-up examination
with magnetic resonance imaging or computed tomography of
the head. The details of the 21 subjects are shown in Table 1
(nonvalvular lone PAF in 15, hypertensive heart disease in 2,
hypertrophic cardiomyopathy in 3, Wolff-Parkinson-White syn-
drome in 1. On the basis of exercise electrocardiographic
tolerance test results, exercise tolerance thallium myocardial
scintigrams and echocardiography, all 21 patients were deter-
mined to have lone PAF. The patients were treated with
various antiarrhythmic agents, such as disopyramide, procain-
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amide, propafenone, verapamil, quinidine, pilcicainide and
digoxin, alone or in combination, but were not given anti-
coagulants. Nine age-matched healthy subjects without
heart disease formed the control group (eight men, one
woman). Written informed consent was obtained from all
patients before the study. The study protocol was in agree-
ment with the guidelines approved by the ethics committee
at our institution.
Blood sampling and assay. Blood samples were taken
during the paroxysmal period of PAF (PAF period), and
antiarrhythmic agents were administered intravenously or
orally to defibrillate and to suppress PAF. Seven days after
recovery of normal sinus rhythm (non-PAF period), blood
samples were again taken under the same conditions. Blood
specimens in the control group were taken in the fasting state.
The blood samples were taken from the cubital vein with the
double-syringe method, using a 21-gauge needle and a 25-ml
syringe (Nipro Co.). These specimens were distributed within
2 min, gently mixed by inverting the vials and immediately
chilled in an ice bath, followed by centrifuging at 3,000 g for
10 min at 248C. The serum was immediately frozen at below
2308C and stored for 2 days before analysis. Prothrombin
time, activated partial thromboplastin time, thrombin-
antithrombin III complex levels and fibrinogen levels were
estimated as indexes of the coagulation system. D-Dimer and
plasmin inhibitor complex levels were examined for the fi-
brinolytic system, and beta-thromboglobulin and platelet fac-
tor 4 levels were used to estimate platelet activity. Peripheral
blood cell count, including hemoglobin and hematocrit, was
also evaluated. Prothrombin time was measured by the one-
step method of Quick (17) (Thromboplastin C Kit, Baxter
Dade), and activated partial thromboplastin time was evalu-
ated with the ellagic-acid activation method (Data-Fi APTT,
American Dade). Thrombin-antithrombin III complex,
beta-thromboglobulin and platelet-factor 4 were measured
by the enzyme-linked immunosorbent assay method (18,19)
(Enzygnost TAT kit, Boehringberke, Asserachrom beta-
thromboglobulin and platelet factor 4, Boehringer-
Mannheim). Levels of D-dimer and plasmin inhibitor complex
were determined using the EIA method (20,21) (D-dimer:
LPIA-ACE, Baxter; plasmin inhibitor complex: Teijin alpha2-
plasmin inhibitor complex, EIA-B). Fibrinogen was measured
with the thrombin method (Fibrinogen a-BMY, Boehringer-
Mannheim).
Statistical analysis. Clinical variables are expressed mean
value 6 SD. The effects of the duration from the onset of PAF
on platelets and coagulation were analyzed by two-way re-
peated measures analysis of variance (ANOVA) (Abacus
Concepts, Inc., Statview 4.02J). Intergroup differences were
analyzed by a paired t test, and differences between patients
and control subjects were analyzed by an unpaired t test for
independent samples and separate variances. When the vari-
ances between each group differed considerably, we used a
nonparametric test (Mann-Whitney U test or Wilcoxon signed
rank test). Correlation between variables was evaluated using
the Pearson correlation coefficient. The Fisher exact probabil-
ity test and receiver operating characteristic analysis were used
to evaluate the point at which the coagulation variables began
Abbreviations and Acronyms
AF 5 atrial fibrillation
ANOVA 5 analysis of variance
CAF 5 chronic atrial fibrillation
PAF 5 paroxysmal atrial fibrillation
Table 1. Patient Characteristics
PAF-I Group PAF-II Group Control Group
Pt No./
Gender
Age
(yr)
Time
(min)
Underlying
Disease Medication
Pt No./
Gender
Age
(yr)
Time
(min)
Underlying
Disease Medication
Pt No./
Gender
Age
(yr)
1/M 56 180 Lone PAF DP, PA 1/M 60 1,110 HCM DP, PA, PRF 1/M 63
2/M 53 585 HCM DP 2/F 49 1,140 WPW DP 2/M 51
3/F 77 420 HHD DP 3/M 49 1,440 Lone PAF DP 3/M 43
4/M 53 275 Lone PAF DP, PA 4/M 43 960 Lone PAF DP 4/M 63
5/M 63 140 Lone PAF DP, PA, VER 5/M 66 780 HHD DP, PA, QUN 5/M 42
6/M 61 450 Lone PAF DP 6/F 56 900 HCM DP 6/M 66
7/M 48 190 Lone PAF DP, PA 7/M 56 960 Lone PAF DP, PLC 7/M 70
8/M 67 80 Lone PAF DP, PA, PRF 8/M 58 880 Lone PAF DP, PRF, VER 8/M 72
9/M 49 680 Lone PAF DP 9/M 71 780 Lone PAF DP, PLC 9/F 56
10/F 77 345 Lone PAF DP, PA 10/F 69 1,000 Lone PAF DIG, DP
11/F 61 480 Lone PAF DP
Mean 57.7 348 Mean 60.5 995 Mean 58.4
6SD 69.1 6193 6SD 610.0 6197 6SD 611.4
DIG 5 digoxin; DP 5 disopyramide; F 5 female; HCM 5 hypertrophic cardiomyopathy; HHD 5 hypertensive heart disease; M 5 male; PA 5 procainamide;
PAF5 paroxysmal atrial fibrillation; PAF-I5 time from onset of paroxysmal atrial fibrillation#12 h; PAF-II5 time from onset of paroxysmal atrial fibrillation.12 h;
PLC 5 pilsicainide; PRF 5 propafenone; QUN 5 quinidine; VER 5 verapamil; Time 5 sampling time from onset of paroxysmal atrial fibrillation; WPW 5
Wolff-Parkinson-White syndrome.
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to increase significantly from the onset of PAF. All tests were
two-tailed, and p, 0.05 was considered statistically significant.
Results
Table 2 shows the values obtained during the PAF and
non-PAF periods in the PAF and control groups. Hematocrit,
hemoglobin, thrombin-antithrombin III complex and platelet
factor 4 values during the PAF period were significantly higher
than those during the non-PAF period and in the control
group. Levels of the beta-thromboglobulin during the PAF
period were also significantly higher than those during the
non-PAF period but did not differ from those in the control
group (p5 0.10). These results showed that AF itself increased
hemoconcentration and enhanced platelet aggregation and
coagulation. When we investigated the relation between the
duration of PAF and these fibrinocoagulation variables, there
were positive correlations between the duration of PAF and
the values of platelet factor 4, beta-thromboglobulin, fibrino-
gen and thrombin-antithrombin III complex in all 21 patients
(Fig. 1 to 4). Statistical analysis revealed that the values of
beta-thromboglobulin and platelet factor 4 began to increase
significantly 12 h after the onset of PAF. On the basis of these
results, the 21 patients were classified into two groups: PAF-I
group (blood specimens collected $12 h of the onset of PAF)
and PAF-II group (blood specimens collected .12 h of onset
of PAF) (Table 3). To clarify the effect of the duration of PAF
on platelet activity and coagulation, the data were then rean-
alyzed between the PAF and non-PAF periods in PAF-I and
PAF-II group patients by two-way repeated measures
ANOVA. Hematocrit and hemoglobin values measured during
the PAF period were significantly higher than those during the
non-PAF period in both group PAF-I and PAF-II and tended
to be higher than those in control group (Table 3).
Beta-thromboglobulin and platelet factor 4 values mea-
sured during the PAF period in the PAF-II group were
significantly higher than those in the PAF-I group (p , 0.001,
ANOVA) (Fig. 5 and 6). Thrombin-antithrombin III complex
and fibrinogen values during the PAF period in the PAF-II
Figure 1. Correlation between platelet factor 4 and time from onset of
PAF. Positive correlation was demonstrated between duration of PAF
and platelet factor 4 levels and began to increase significantly at 12 h
after the onset of PAF.
Figure 2. Correlation between beta-thromboglobulin and time from
onset of PAF. Positive correlation was demonstrated between duration
of PAF and beta-thromboglobulin levels and began to increase signif-
icantly at 12 h after the onset of PAF.
Table 2. Fibrinocoagulation Variables During Paroxysmal and Nonparoxysmal Atrial Fibrillation Periods in 21 Patients and 9 Control Subjects
PAF Period (A) Non-PAF Period (B) Control (C)
p Value
A vs. B A vs. C
Hct (%) 46.0 6 3.96 43.4 6 3.58 42.8 6 3.19 ,0.001 ,0.05
Hb (g/dl) 15.3 6 1.41 14.4 6 1.34 13.8 6 1.13 ,0.0001 ,0.05
PT (s) 11.2 6 1.22 10.9 6 1.40 11.8 6 0.54 NS NS
aPTT (s) 31.6 6 3.37 30.7 6 2.97 30.3 6 2.56 NS NS
TAT (mg/liter) 6.68 6 5.11 4.21 6 3.67 3.11 6 1.86 ,0.05 ,0.05
Fbg (mg/dl) 262.2 6 65.4 257.8 6 56.2 225.7 6 37.5 NS NS
D-dimer (ng/ml) 141.7 6 208.6 127.7 6 207.0 67.2 6 31.7 NS NS
PIC (mg/ml) 0.86 6 0.44 0.90 6 0.43 1.02 6 0.31 NS NS
Beta-TG (ng/ml) 38.0 6 27.3 29.1 6 21.2 22.8 6 7.85 ,0.05 0.10
PF4 (ng/ml) 16.4 6 18.2 10.3 6 11.1 3.37 6 2.26 ,0.05 ,0.05
*Seven days after recovery of sinus rhythm. Data presented are mean value6 SD. aPTT5 activated prothrombin time; Fbg5 fibrinogen; Hb5 hemoglobin; Hct5
hematocrit; PAF 5 paroxysmal atrial fibrillation; PF4 5 platelet factor 4; PIC 5 plasmin inhibitor complex; PT 5 prothrombin time; TG 5 thromboglobulin.
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group tended to be higher than those in the PAF-I group but
were not significantly higher (p 5 0.06, ANOVA) (Fig. 7 and
8). These results indicate that the duration of PAF influences
platelet activity and coagulability. Furthermore, beta-
thromboglobulin and platelet factor 4 values during the non-
PAF period in the PAF-II group were significantly higher than
those in the control group. Prothrombin time during the PAF
period in the PAF-II group was shortened compared with that
in the control group (Fig. 9); however, activated partial throm-
boplastin time and D-dimer and plasmin inhibitor complex
values did not differ significantly between groups.
Discussion
According to the Cerebral Embolism Task Force (7),
cerebral embolism induced by heart disease occurs in 6% to
23% of all patients with a cerebral infarction, whereas 45% are
caused by nonvalvular AF, indicating the importance of non-
valvular AF for the risk of stroke. According to the Framing-
ham Study (8), the incidence of stroke in patients with AF
without rheumatic heart disease is five times higher than that
in patients without AF. Furthermore, if AF is present with
rheumatic heart disease, the incidence of stroke becomes 17
times higher than that without AF. Moreover, in a report on
the incidence of stroke in patients with PAF, Petersen and
Gotfredsen (13) reported that of 426 patients with PAF, 33%
developed CAF and that the incidence of stroke tended to be
higher in the first year after this development. According to
Takahashi et al. (14), the incidence of stroke was 6.4% over a
10-year follow-up period in patients with PAF, whereas
Kuramoto et al. (15) reported the incidence of stroke to be
about 32% of that in patients with CAF (15). These findings
suggest that although PAF might be a risk factor for stroke, it
might not be as great a risk factor as CAF. Three mechanisms
for the development of stroke in patients with AF have been
proposed (22–24): 1) reduction of cerebral blood flow; 2)
hemoconcentration; and 3) activation of the coagulation sys-
tem. With regard to reduction of cerebral blood flow, Lavy et
al. (24) reported that in patients with AF, cerebral blood flow
was reduced by 5.5% to 17.5% compared with that in patients
with normal sinus rhythm. As for hemoconcentration during
PAF (25), it could be that secretion of vasopressin is sup-
pressed by left atrial distention (26), and secretion of atrial
Figure 3. Correlation between fibrinogen and time from onset of PAF.
Fibrinogen levels and duration of PAF demonstrated positive corre-
lation.
Figure 4. Correlation between thrombin-antithrombin III complex
(TAT) and time from onset of PAF. Thrombin-antithrombin III
complex levels and duration of PAF demonstrated positive correlation.
Table 3. Comparison of Fibrinocoagulation Variables Between PAF-I and PAF-II Groups and Control Subjects
PAF-I Group (n 5 11) PAF-II Group (n 5 10)
Control Group
(n 5 9)PAF Period Non-PAF Period PAF Period Non-PAF Period
Hct (%) 45.9 6 3.91* 43.6 6 2.90 46.0 6 4.23* 44.0 6 3.72 42.8 6 3.19
Hb (g/dl) 15.3 6 1.34† 14.2 6 1.02 15.2 6 1.56† 14.5 6 1.66 13.8 6 1.13
PT (s) 12.0 6 0.77 11.7 6 1.11 10.3 6 0.98‡ 10.0 6 1.20‡ 11.8 6 0.54
aPTT (s) 32.6 6 2.37 30.7 6 2.67 30.4 6 4.01 30.6 6 3.43 30.3 6 2.56
TAT (mg/liter) 4.62 6 3.44 3.37 6 2.18 8.94 6 5.82‡§ 5.12 6 4.78 3.11 6 1.86
Fbg (mg/dl) 229.9 6 28.0 246.1 6 39.8 297.8 6 77.2†§ 270.7 6 69.9 225.7 6 37.5
D-dimer (ng/ml) 70.26 43.0 90.6 6 79.3 220.4 6 285.5 168.6 6 291.0 67.2 6 31.7
PIC (mg/ml) 0.71 6 0.42 0.74 6 0.31 1.02 6 0.42 1.07 6 0.49 1.02 6 0.31
Beta-TG (ng/ml) 18.7 6 5.66 17.9 6 6.18 59.3 6 25.7\¶ 41.5 6 25.2† 22.8 6 7.85
PF4 (ng/ml) 3.54 6 1.45 3.44 6 1.70 30.5 6 17.7\¶ 17.8 6 12.2‡ 3.37 6 2.26
*p 5 0.07, †p , 0.05, ‡p , 0.01, ¶p , 0.001 versus Control Group. §p 5 0.06, \p , 0.001 versus paroxysmal atrial fibrillation (PAF) period in PAF-I group (by
analysis of variance). Data presented are mean value 6 SD. Abbreviations as in Tables 1 and 2.
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natriuretic peptide is increased (27,28). In addition, the find-
ings of several studies that examined activation of the coagu-
lation system indicated increased levels of thrombin-
antithrombin III complex and D-dimer and decreased levels of
protein C (29); increased levels of fibrinogen, D-dimer, beta-
thromboglobulin and platelet factor 4 (1,3,4); and increased
levels of prothrombin fragment F112, thrombin-antithrombin
III complex (6) and fibrinopeptide A (12).
However, these investigations were performed only in pa-
tients with CAF, with patients without AF as the control group.
Thus, it is not clear whether these coagulation abnormalities
are attributable to AF alone or to the pathologic state that
underlies AF. To clarify this issue, we examined the same
patients during AF and at recovery of normal sinus rhythm.
Hence, we investigated the dynamics of fibrininocoagulation in
the paroxysmal and nonparoxysmal states in patients with
PAF. According to our previous study (16), hemoconcentra-
tion only was observed within 6 h of the onset of AF, with no
evidence of hypercoagulation. However, in one patient a
hypercoagulative state maintained the AF for ;20 h. Thus, we
hypothesized that the duration of AF might be related to
hypercoagulability. During the PAF period in the PAF-II
group, beta-thromboglobulin and platelet factor 4 levels were
significantly higher than those in the PAF-I group, and
thrombin-antithrombin III complex and fibrinogen levels
tended to be higher. Furthermore, even at 7 days after recovery
of normal sinus rhythm, a significant increase in beta-
thromboglobulin and platelet factor 4 levels and a reduction in
prothrombin time were observed in the PAF-II group com-
pared with these variables in the control group. Thrombin-
antithrombin III complex and fibrinogen levels also tended to
increase. In addition, a positive correlation was found between
the duration of PAF and beta-thromboglobulin, platelet factor
4, thrombin-antithrombin III complex and fibrinogen levels.
These findings indicate that acceleration of platelet activity
and hypercoagulability developed 12 h (16 h on average) after
the onset of PAF and were prolonged for 1 week after the
recovery of normal sinus rhythm.
Acceleration of platelet activity and hypercoagulability
during PAF. The development of accelerated platelet activity
and hypercoagulability appears to be related to 1) irregular
atrial wall motion, which causes abnormal atrial blood flow and
injury to the endothelium; and 2) platelet aggregation and
frequent collision of platelets, which leads to acceleration of
platelet activity (30,31). Furthermore, tissue factors that are
released from subendothelial tissue at the location of the
endothelial injury bind to tissue factors in the presence of
platelet-factor 3 to form thrombin and fibrinogen (32). This
event accelerates the extrinsic coagulation cascade, resulting in
the shortening of prothrombin time. The hemoconcentration
that developed during AF was induced by increased secretion
of atrial natriuretic peptide and decreased secretion of vaso-
pressin (25). The increased hematocrit induced by hemocon-
centration influences the acceleration of platelet thrombus
formation, together with a hydrodynamic change in shear flow
(30,31). This might be one reason for the acceleration of
Figure 5. Comparisons of beta-thromboglobulin between PAF and
non-PAF periods in the PAF groups and control subjects (C). non-
PAF period 5 7 days after return to sinus rhythm; PAF I 5 blood
samples collected #12 h of onset of PAF; PAF II 5 blood samples
collected.12 h of onset of PAF. *p, 0.05, **p, 0.001 versus control
group. $p , 0.001 (ANOVA) versus PAF-I group during PAF period.
Figure 6. Comparisons of platelet factor 4 between PAF and non-PAF
periods in the PAF groups and control subjects. Abbreviations and p
values as in Figure 5.
Figure 7. Comparisons of thrombin-antithrombin III complex (TAT)
between PAF and non-PAF periods in the PAF groups and control
subjects. Other abbreviations as in Figure 5. *p , 0.01, #p 5 0.14
versus control group. $p 5 0.06 (ANOVA) versus PAF-I group during
PAF period.
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platelet activity observed in the present study. Therefore,
platelet activity is increased ;12 h after the onset of PAF,
aiding the formation of thrombosis. Thus, as shown in Stroke
Prevention in Atrial Fibrillation trials I and II (33,34), admin-
istration of antiplatelet drugs is important to prevent the
occurrence of stroke induced by AF.
Lone AF and thrombotic tendency. Lone AF has been
considered a benign, low risk factor for stroke (35). A retro-
spective study of patients with lone AF from the Mayo Clinic
(36) found that only 1.3% of patients with lone AF had a
stroke during the 15-year follow-up period. Gajewski et al. (37)
reported that the overall prognosis of patients with chronic AF
is worse than that of patients with lone AF. Chronic AF
increased mortality seven- to eightfold compared with that in
control subjects with sinus rhythm, whereas paroxysmal AF
increased mortality no more than twofold (37). However,
evidence from the Framingham Study (38) has suggested
otherwise. The risk of stroke during the 30 years of follow-up
in ;5,000 subjects was 28% in patients with lone AF and 7%
in control subjects without AF (38). In the present study, AF
itself enhances platelet aggregation and coagulation, especially
if the duration of AF was .12 h, with or without underlying
disease. This finding suggests that even lone AF increases the
risk of stroke if the duration of AF is .12 h.
Study limitations. The PAF-II group demonstrated con-
siderable elevation in thrombin-antithrombin III complex,
fibrinogen, D-dimer, beta-thromboglobulin and platelet factor
4 levels, even in the AF-free period. Therefore, we believe that
AF .12 h in duration might cause a relatively long-term
change in platelet activation and coagulation; however, we did
not measure these variables a later time point to determine
when they returned to normal levels or whether the fibrinolytic
system was accelerated and fibrinocoagulative equilibrium was
reached. Although the antiarrhythmic drugs differed in each
patient with regard to type and amount, we did not examine
platelet function and coagulation, which may have been af-
fected by these agents. Therefore, further studies should
address these issues.
Clinical implications. According to our results, accelera-
tion of platelet activity and the hypercoagulative state occurred
at least 12 h (16 h on average) after the onset of PAF. Thus,
defibrillation should be performed within 12 h of the onset of
AF, and anticoagulant therapy, including suppression of plate-
let activity, is required when AF continues for .12 h.
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